WO2014082286A1 - Analogue de la rapamycine et procédés de fabrication associés - Google Patents
Analogue de la rapamycine et procédés de fabrication associés Download PDFInfo
- Publication number
- WO2014082286A1 WO2014082286A1 PCT/CN2012/085631 CN2012085631W WO2014082286A1 WO 2014082286 A1 WO2014082286 A1 WO 2014082286A1 CN 2012085631 W CN2012085631 W CN 2012085631W WO 2014082286 A1 WO2014082286 A1 WO 2014082286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- mmol
- substituted
- immune
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 62
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 201000011510 cancer Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 18
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 14
- 229940002612 prodrug Drugs 0.000 claims abstract description 13
- 239000000651 prodrug Substances 0.000 claims abstract description 13
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 201000005202 lung cancer Diseases 0.000 claims abstract description 8
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 7
- 210000003734 kidney Anatomy 0.000 claims abstract description 7
- 210000004072 lung Anatomy 0.000 claims abstract description 7
- 210000004185 liver Anatomy 0.000 claims abstract description 6
- 210000004556 brain Anatomy 0.000 claims abstract description 4
- 201000010174 renal carcinoma Diseases 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 238000001990 intravenous administration Methods 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 170
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 17
- -1 amino, carbonyl Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 238000002054 transplantation Methods 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 210000004087 cornea Anatomy 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 210000003414 extremity Anatomy 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract description 54
- 229940079593 drug Drugs 0.000 abstract description 17
- 210000001519 tissue Anatomy 0.000 abstract description 12
- 208000037803 restenosis Diseases 0.000 abstract description 9
- 210000000056 organ Anatomy 0.000 abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 5
- 206010009944 Colon cancer Diseases 0.000 abstract description 5
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000002538 fungal effect Effects 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 210000004351 coronary vessel Anatomy 0.000 abstract description 2
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract 3
- 210000001367 artery Anatomy 0.000 abstract 2
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 101710088998 Response regulator inhibitor for tor operon Proteins 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 210000003128 head Anatomy 0.000 abstract 1
- 210000003739 neck Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 68
- 239000000243 solution Substances 0.000 description 64
- 239000007787 solid Substances 0.000 description 61
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- 239000000543 intermediate Substances 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 41
- 229960002930 sirolimus Drugs 0.000 description 41
- 239000003480 eluent Substances 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 27
- 239000011734 sodium Substances 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 21
- 239000012267 brine Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 159000000000 sodium salts Chemical class 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 10
- 229940126062 Compound A Drugs 0.000 description 10
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 7
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229960003444 immunosuppressant agent Drugs 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- 229960001967 tacrolimus Drugs 0.000 description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000182988 Assa Species 0.000 description 3
- 208000009137 Behcet syndrome Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 206010000804 Acute hepatic failure Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000775881 Haematopota pluvialis Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 2
- 241001647839 Streptomyces tsukubensis Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940042992 afinitor Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950000844 mizoribine Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 235000000010 nanu Nutrition 0.000 description 2
- 244000082862 nanu Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UBQBKOBGHRTZRG-UPAXIQFWSA-N 104987-09-9 Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 UBQBKOBGHRTZRG-UPAXIQFWSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- HTFNVAVTYILUCF-UHFFFAOYSA-N 2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methyl-11-methylsulfonylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(c2n1)S(C)(=O)=O)C(=O)N1CCC(CC1)N1CCN(C)CC1 HTFNVAVTYILUCF-UHFFFAOYSA-N 0.000 description 1
- YGDVXSDNEFDTGV-UHFFFAOYSA-N 2-[6-[bis(carboxymethyl)amino]hexyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCCCCCN(CC(O)=O)CC(O)=O YGDVXSDNEFDTGV-UHFFFAOYSA-N 0.000 description 1
- PPXUUPXQWDQNGO-UHFFFAOYSA-N 2-azidoacetic acid Chemical compound OC(=O)CN=[N+]=[N-] PPXUUPXQWDQNGO-UHFFFAOYSA-N 0.000 description 1
- BSULWPSUVMOMAN-UHFFFAOYSA-N 2-azidoethanol Chemical compound OCCN=[N+]=[N-] BSULWPSUVMOMAN-UHFFFAOYSA-N 0.000 description 1
- PQXPAFTXDVNANI-UHFFFAOYSA-N 4-azidobenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1 PQXPAFTXDVNANI-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- AOPMJTXVTVQAGD-KNLBXDFQSA-N 5,6,8,11,12,13,14,15,16,17,18,19,23,24,25,25a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-15,19-epoxy-1h,3h-pyrrolo(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h)-tetrone Chemical compound C1CC(O)C(OC)CC1\C=C(/C)C1C(C)C(O)CC(=O)C(CC=C)\C=C(C)/CC(C)CC(OC)C(C(CC2C)OC)OC2(O)C(=O)C(=O)N2CCCC2C(=O)O1 AOPMJTXVTVQAGD-KNLBXDFQSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- XFZZDIHCNHYESF-UHFFFAOYSA-N 7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-one Chemical compound C=12CC(=O)C(N)CCC2=C(Br)C=CC=1C1=CC=CC=C1 XFZZDIHCNHYESF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010066968 Corneal leukoma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000960558 Dipha Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- AXSPHUWXYSZPBG-UHFFFAOYSA-N Gusperimus hydrochloride Chemical compound Cl.Cl.Cl.NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N AXSPHUWXYSZPBG-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000820057 Ithone Species 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical group [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 231100000579 Toxinosis Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002769 anti-restenotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- ZDQSOHOQTUFQEM-NURRSENYSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-NURRSENYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000011797 cavity material Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 101150089929 figl-1 gene Proteins 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000009750 upstream signaling Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
Definitions
- cyclosporine (cyclosporin A) has found wide use since its introduction in the fields of organ transplantation and immunomodulation, and has brought about a significant increase in the success rate for transplantation procedures.
- macrocyclic compounds having potent immunomodulatory activity have been discovered.
- FR-900520 and FR-900523. which differ from FK-506 in their alkyl substituent at C-21. have been isolated from S. hygroscopicus yakushimnaensis.
- FR-900525, produced by S. tsukubaensis differs from FK- 506 in the replacement of a pipecolic acid moiety with a proline group.
- Unsatisfactory side- effects associated with cyclosporine and FK-506. such as nephrotoxicity, have led to a continued search for immunosuppressant compounds having improved efficacy and safety, including an immunosupressive agent which is effective topically, but ineffective systemically (U.S. Pat. 5.457.1 I I).
- Rapamycin as illustrated below, is a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus. which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo (US 3.929.992 and US 3.993.749).
- Rapamycin alone (US 4.885.171) or in combination with picibanil (US 4,401.653) has been shown to have antitumor activity.
- rapamycin was also shown to be effective as an immunosuppressant in the experimental allergic encephalomyelitis model, a model for multiple sclerosis: in the adjuvant arthritis model, a model for rheumatoid arthritis: and was shown to effectively inhibit the formation oflgE-like antibodies.
- Rapamycin was recently synthesized in its naturally occurring enantiomeric form (K. C. Nicolaou et al.. J. Am. Chem.
- rapamycin analog is a tetrazole containing rapamycin analog (US 6,015.815). The tetrazole heterocyclic ring is used to replace the hydroxyl group to effect the analog.
- rapamycin analogs which possess potentially enhanced efficacy against broad spectrum of cancers such as renal cell carcinoma, breast cancers, head and neck cancers, and potentially better lipophilicity. longer half live in the blood or in local tissues, or resistance to oxidative forces and better stability in a formulation.
- One way to achieve these goals is through introduction of a tria/.ole moiety to the side chain of a rapamycin which may impart a better lipophilicity.
- modified rapamycin may also have better potency against a variety of cancers, and potentially reduced toxicities.
- one object of the present invention is to provide novel semi-synthetic rapamycin analogs which possess a desired tria/.ole moiety attached to either or both to 31C-. and or 42C-position of a rapamycin molecule.
- the present invention is directed to compounds represented by the structural formula illustrated below.
- the present invention is directed to compounds represented by the structural formula illustrated below.
- a compound of the present invention may contain two such substitutes at both the 42C and 31 C-positions of a rapamycin.
- A' is one of the following structures:
- Another object of the present invention is to provide a synthetic processes for the preparation of such compounds from starting materials obtained by fermentation, as well as chemical intermediates useful in such synthetic processes.
- a further object of the present invention is to provide pharmaceutical compositions containing, as an active ingredient, at least one of the above compounds.
- Yet another object of the present invention is to provide a method of treating a variety of disease states, including restenosis, post-transplant tissue rejection, immune and autoimmune dysfunction, fungal growth, and cancer.
- the compounds of the present invention may be employed as an oral tablet, oral solid or oral liquid, oral immediate or sustained release dosage, intravenous injection dosages, parenteral dosages, cream or solutions by formulation w ith pharmaceutically acceptable vehicles.
- compositions for immediate release or sustained release of its active ingredient each comprising a compound of this invention and pharmaceutical ly acceptable excepient.
- FIG. 1 Graph for Renal cell carcinoma tumor cell inhibition studies
- FIG. 2 Graph for Renal cell carcinoma tumor cell inhibition studies
- FIG. 3 Graph for Lung Cancer A549 cell inhibition studies
- FIG. 4 Graph for Lung Cancer A549 cell inhibition studies
- FIG. 5 Graph for Lung Cancer A549 cell inhibition studies
- FIG. 6 Graph for Melanoma SK-MEL-28 cell inhibition studies: FIG. 7 Graph for Melanoma SK-MEL-28 cel l inhibition studies: FIG. 8 Graph for Melanoma SK-MEL-28 cell inhibition studies: FIG. 9 Graph for Epidermal cancer A43 I tumor cell model:
- FIG. 10 Graph for Epidermal cancer A43 I tumor cel l model:
- FIG. 1 1 Graph for Epidermal cancer ⁇ 43 I tumor cel l model :
- FIG. 12 Graph for Glioblastoma U87 MG Tumor model studies: FIG. 13 Graph for Glioblastoma U87 MG Tumor model studies; FIG. 14 Graph for Glioblastoma U87 MG Tumor model studies: FIG. 15 Graph for Human colorectal tumor HCT l I 6 model studies; FIG. 16 Graph for H uman colorectal tumor HCT l 16 model studies; FIG. 17 C]raph for Human colorectal tumor HCT I 1 6 model studies: FIG. 18 Graph for Breast cancer MDA-MB-23 I tumor model;
- FIG. 19 Graph for Breast cancer M DA-MB-23 l tumor model: FIG. 20 Graph for Breast cancer M DA-MB-23 I tumor model; FIG. 21 Graph for Breast cancer MCF-7 tumor model:
- FIG. 22 Graph for Breast cancer MCF-7 tumor model
- FIG. 23 Graph for Breast cancer MCF-7 tumor model:
- FIG. 24 Cjraph for Prostate cancer PC-3 tumor studies:
- FIG. 25 Graph for Prostate cancer PC-3 tumor studies
- FIG. 26 Graph for Prostate cancer PC-3 tumor studies: FIG.27 Efficacy of rapamycin analog of the present invention in treating HCT 116.
- prodrug. refers to compounds which are rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood.
- a thorough discussion is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems.” Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., "Bioreversible Carriers in Drug Design.” American Pharmaceutical Association and Pergamon Press. 1987. both of which are hereby incorporated by reference.
- prodrugs refers to those prodrugs of the compounds of the present invention which are. within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower mammals without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. as well as the zwitterionic forms, where possible, of the compounds of the present invention.
- Particularly preferred pharmaceutically acceptable prodrugs of the present invention are prodrug esters of the C-31 hydroxyl group of compounds of the present invention.
- prodrug esters refers to any of several ester-forming groups that are hydro lyzed under physiological conditions.
- Examples of prodrug ester groups include acetyl, ethanoy!. pivaloyl. pivaloyloxymethyl. acetoxymethyl. phthalidyl. methoxymethyl. indanyl. and the like, as well as ester groups derived from the coupling of naturally or unnaturalh-occurring amino acids to the C- 1 hydroxyl group of compounds of the present invention.
- epimer refers to a compound having the identical chemical formula but a different optical configuration at a particular position.
- a 42-Epi rapamycin refers to the compound that has the opposite optical rotation compared to the rapamycin obtained by a fermentation process.
- the term “15-isomer” as used herein, refers to the analog of rapamycin that contains a 7- member ring at the 15-position as opposed to a regular rapamycin obtained from a fermentation process which contains a six-member ring. This kind of conversion is also called “tautomcrization " .
- the 15-isomer "' as used herein, may also be referred to as a 15 tautomer of a rapamycin.
- the compounds of the present invention may be prepared by a variety of synthetic routes. Most of the common conjugation reactions of rapamycin at 42- and/or 31-hydroxyl positions are found in the rapamycin patents mentioned above, the contents of which are incorporated herein by reference in their entireties.
- Rapamycin Derivatives The parent rapamycin structure is shown below .
- Example 3 Synthesis of Compound A4 [31] To a solution of rapamycin ⁇ (200 mg. 0.2 mmol) and 4- azidobenzoic acid (100 mg.0.6 mmol) in anhydrous THF (9 ml.) was added DIPEA (100 ⁇ L ⁇ . 0.6 mmol) and Cul (20 mg.0.1 mmol) under N;. The solution was stirred at rt for 3 hours. Then. 20 ml. water was added and extracted with ethyl acetate (20 ml. x 3). The combined organic layer was washed b brine and dried over anhydrous a ⁇ S .).
- R and B have the following structures in some examples of the B series of rapamycin derivatives.: HO
- CDCI 3 67.88 (m.311).7.12 (m.211).6.39-6.01 (m.4H).5.42-4.63 (m.4H): I.CMS (m/z) ES- 1148 (M-H) " .
- m TOR kinase activity is regulated by several upstream signaling pathwa s and its dysreg lation has been implicated in several forms of cancer.
- a Terbium labeled ant i- phosphorv lated 4I/-BPI antibodv to detect phosphorylation of the Of ['-labeled substrate b ⁇ m TOR. This ⁇ - ⁇ RITI based assay can be used to screen inhibitors of mTOR in vitro.
- DMSO was 10-fold diluted with ddH20. so the compounds were in 10% DMSO.
- the kinase reaction was started by the addition of 2.5 ⁇ of a solution of ATP (ATP.200 ⁇ > inal cone, in the 5 ⁇ volume is 10 ⁇ ) and substrate (0.8 ⁇ > final cone, in the 5 ⁇ assa> volume is 0.4 ⁇ ) in assay buffer and the resulting mixture was incubated for 18 min at 22°C.
- ATP ATP.200 ⁇ > inal cone, in the 5 ⁇ volume is 10 ⁇
- substrate 0.8 ⁇ > final cone, in the 5 ⁇ assa> volume is 0.4 ⁇
- Y was the normalized "oinhibition value.
- X was the log value of the test compound concentration, i 50 was the concentration of compound where half of maximal inhibition was achieved.
- Preparation of culture media and cell culture conditions [91] Prepare the compounds and condition the cells the next day. each chemical compound to be assaved was diluted to 10 mM stock solution with 100% DMSO. followed by additional dilution with 1 0% DMSO diluted to 2 mM. followed serial 5X dilution using serum-free cell culture medium to a final 10 different diluted concentrations points (2000.400.80. 16.3.2.0.64. 0.128.0.0256.0.00512.0.00102 ⁇ ). plus 0.5% DMSO (no compound) as a maximum control and ⁇ Rapamycin as a minimum control. A solution of 0.5 ⁇ of each diluted compound is added to the ⁇ of cell culture plate, the final compound concentration of 10 points ( 10.2.0.4. 0.08.
- Fpidermal cancer ⁇ 431 tumor cell model Fig9, Fig 10 and Figl 1.
- n animal number: Dosing volume: adjust dosing volume based on bod weight 10 ⁇ /g). Treatment schedule may be adjusted ifbodv weight loss > 15%.
- [1011 l-ndpoints The major endpoinl is to see if the tumor growth can be delayed or mice can be cured. Tumor sizes will be measured t ice w ekly in two dimensions using a caliper, and the volume will be expressed in mm3 using the formula: V - 0.5 a x b2 where a and b are the long and short diameters of the tumor, respectively. The tumor sizes are then used for the calculations of both T-C and T/C values. f-C is calculated with T as the median time (in days) required for the treatment group tumors to reach a predetermined size (e.g.. 500 mm3). and C is the median time (in days) for the control group tumors to reach the same size.
- T the median time (in days) required for the treatment group tumors to reach a predetermined size (e.g.. 500 mm3).
- C is the median time (in days) for the control group tumors to reach the same size.
- the /C value (in percent) is an indication of antitumor effectiveness.
- T and C are the mean volume of the treated and control groups, respectively, on a given day. Tumor tissues will be collected for the tumor weight and photo at the end of (he si Lid ⁇ .
- lop line (diamond) is for Vehicle
- second line (triangle) is for B7 at 3 mg/kg dose:
- third line (purple cross) represents B7 at 9gm kg dose:
- fourth line from the top (pink squared represent Afinitor at 9 mg/kg dose),
- the bottom line (blue cross) represents B7 a I 8 mg kg dose.
- the compounds of the present invention possess immunomodulatory and anti-tumor activity in mammals (especially humans).
- immunosuppressants the compounds of the present invention are useful for the treatment and prevention of immune-mediated diseases such as the resistance by transplantation of organs or tissue such as heart, kidney, liver, medulla ossium. skin, cornea, lung, pancreas, intestinum tonne, limb, muscle, nerves, duodenum, small-bowel, pancrcatic-islet-cell. and the like: diseases brought about by medulla ossium transplantation: autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus.
- Hashimoto's th oiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, glomerulonephritis, and the like further uses include the treatment and prophylaxis of inilammatory and by perproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses, such as psoriasis, atopic dermatitis, contact dermatitis and further eczematous dermatitises, is scborrhocis dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas.
- vasculitides erythemas, cutaneous eosinophijias. lupus erythematosus, acne and alopecia areata: various eye diseases (autoimmune and otherwise) such as keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialts corneae. corneal leukoma, and ocular pemphigus.
- various eye diseases such as keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialts corneae. corneal leukoma, and ocular pemphigus.
- reversible obstructive airway disease which includes conditions such as asthma (for example, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma), particularly chronic or inveterate asthma (for example, late asthma and airway hyper-responsiveness), bronchitis, allergic rhinitis, and the like are targeted by compounds of the present invention.
- asthma for example, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma
- chronic or inveterate asthma for example, late asthma and airway hyper-responsiveness
- bronchitis allergic rhinitis
- Inllammalion of mucosa and blood vessels such as gastric ulcers, vascular damage caused by ischemic diseases and thrombosis.
- lerativ e vascular diseases such as intimal smooth muscle cell hyperplasia, restenosis and vascular occlusion, particularly following biologically- or mechanically-mediated vascular injury, may be treated or prevented by the compounds of the present invention.
- Other treatable conditions include ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal inflammations/allergies such as Coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis. Crohn's disease and ulcerative colitis: nervous diseases such as multiple myositis. (iuillain-Barre syndrome.
- Meniere's disease, polyneuritis, multiple neuritis, mononeuritis and radiculopathy endocrine diseases such as hyperthyroidism and Basedow's disease: hematic diseases such as pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia and anerythroplasia: bone diseases such as osteoporosis: respiratory diseases such as sarcoidosis, fibroid lung and idiopathic interstitial pneumonia: skin disease such as dermalomyositis.
- leukoderma vulgaris ichthyosis vulgaris, photoallergic sensitivity and cutaneous T cell lymphoma
- circulatory diseases such as arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa and myocardosis: collagen diseases such as scleroderma.
- adiposis eosinophilic fasciitis: periodontal disease such as lesions of gingiv a, periodontium, alveolar bone and substantia ossea dentis: nephrotic syndrome such as glomerulonephritis: male pattern aleopecia or alopecia senilis by preventing epilation or prov iding hair germination and'or promoting hair generation and hair growth: muscular dystrophy: Pyoderma and Sevan ' s syndrome: Addison's disease: active oxygen-mediated diseases, as for example organ injury such as ischemia-reperl ' usion injury of organs (such as heart, liver, kidney and digestive tract) which occurs upon pres rvation, transplantation or ischemic disease (lor example, thrombosis and cardiac infarction): intestinal diseases such as endotoxin-shock.
- organ injury such as ischemia-reperl ' usion injury of organs (such as heart, liver, kidney and digestive tract) which
- renal diseases such as ischemic acute renal insufficiency and chronic renal insufficiency: pulmonary diseases such as toxinosis caused by lung-oxygen or drug (for example, paracort and bleomycins), lung cancer and pulmonary emphysema: ocular diseases such as cataracta. sidcrosis.
- retinitis, pigmentosa, senile macular degeneration, vitreal scarring and corneal alkali burn dermatitis such as erythema multiforme, linear IgA ballous dermatitis and cement dermatitis: and others such as gingivitis, periodontitis, sepsis, pancreatitis, diseases caused b_ ⁇ environmental pollution (for example, air pollution), aging, carcinogenesis, metastasis of carcinoma and hypobaropalhy : diseases caused by histamine or lcukotricne-C ' .siib.4 release: Behcet's disease such as intestinal-, vasculo- or neuro-Behcet's disease, and also Behcet's which affects the oral cav ity, skin.
- Behcet's disease such as intestinal-, vasculo- or neuro-Behcet's disease, and also Behcet's which affects the oral cav ity, skin.
- the compounds of the present invention may be useful for the treatment and prevention of hepatic disease such as immunogenic diseases (for example, chronic autoimmune liver diseases such as autoimmnune hepatitis, primary biliary cirrhosis and sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxin, viral hepatitis, shock or anoxia).
- immunogenic diseases for example, chronic autoimmune liver diseases such as autoimmnune hepatitis, primary biliary cirrhosis and sclerosing cholangitis
- partial liver resection e.g. necrosis caused by toxin, viral hepatitis, shock or anoxia.
- non-A/non-B hepatitis cirrhosis (such as alcoholic cirrhosis) and hepatic failure such as fulminant hepatic failure, late-onset hepatic failure and " acute-on-chronic " liver failure (acute liver failure on chronic liver diseases), and moreover are useful for various diseases because of their useful activity such as augmention of chemotherapeutic effect, cytomegalovirus infection, particularly I IC V infection, antiinflammatory activity, sclerosing and llbrotic diseases such as nephrosis, scleroderma, pulmonary fibrosis, arteriosclerosis, congestive heart failure, ventricular hypertrophy, postsurgical adhesions and scarring, stroke, myocardial infarction and injur associated with ischemia and rcperfusion. and the like.
- compounds of the present invention possess ⁇ -506 antagonistic properties.
- the compounds of the prcsenl invention may thus be used in the treatment of immunodepression or a disorder involving immunodepression.
- Rxamplcs of disorders involving immunodepression include AIDS, cancer, fungal infections, senile dementia, trauma (including wound healing, surgery and shock) chronic bacterial infection, and certain central nervous system disorders.
- the immunodepression to be treated ma be caused by an overdose of an immunosuppressive macroe die compound, for example derivatives ol ' 12-(2-cyclohcxyl- 1 -methyl vinyl )- 1 .19.21 ,27-tetramethyl- 11.28-dioxa4-azatricyclo
- an immunosuppressive macroe die compound for example derivatives ol ' 12-(2-cyclohcxyl- 1 -methyl vinyl )- 1 .19.21 ,27-tetramethyl- 11.28-dioxa4-azatricyclo
- an immunosuppressive macroe die compound for example derivatives ol ' 12-(2-cycl
- I he compounds of the present invention possess anti-tumor activity in mammals (especially humans).
- the compounds of the invention can be used to treat brain and neurovascular tumors, head and neck cancers, breast cancer, lung cancer, mesothelioma, lymphoid cancer, stomach cancer, kidney cancer, renal carcinoma, liver cancer and liver cirrhosis, ovarian cancer, ovary endometriosis, testicular cancer, skin cancer, melanoma, neuro and all endocrine cancers, spleen cancers, pancreatic cancers, blood proliferative disorders such as I lodgkin ' s cancer, lymphoma, leukemia, and anv cancer disorders that result from uncontrolled cellular proliferations.
- the compounds of the present invention may be mixed with commonly known pharmaceutical excipients such as udragit. sodium carboxymelhv lcellulosc (N'a CM), sodium carboxypropv (cellulose, anv oilier natural Ix derived or svnthetic excipients to effect an efficacious pharmaceutical formulation.
- the formulation comprising the compounds of the invention mav be made as a immediate release formulation, or a sustained release formulation, or site injection depot formulation, depending on the medical needs.
- the compound of the present invention ma ⁇ also be combined with a medical device, such as a stent, a balloon, a balloon catheter, an orthopedic dev ice, lo further enhance the efficacy of the medical device.
- the compound of the present invention may be the main lunction component of a medical treatment regime, such as a local injection formulation, or an ancillary function, such as a coaling on a medical device, or in combination with a low -molecular weight or polymer excipient. and used as a coaling or lillcr of a medical device.
- a medical treatment regime such as a local injection formulation
- an ancillary function such as a coaling on a medical device, or in combination with a low -molecular weight or polymer excipient.
- the compounds of the present invention When used to treat restenosis following a balloon angioplasty or stent placement, the compounds of the present invention, and the native rapamycin. are thought to exhibit their therapeutic functions through the inhibition of the mammalian target of rapamycin or m ' l OR.
- a therapeutically effective amount of one of the compounds of the present invention may be employed in pure form or. where such forms exist, in pharmaceutical! acceptable salt, ester or prodrug form.
- the compound may be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable excipients.
- therapeutically effective amount means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention w ill be decided by the attending ph sician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder: activity of the spec i tic compound employed: the specific composition employed: the age. body weight, general health, sex and diet oflhe patient: the time of administration, route of administration, and rate of excretion of the specific compound employed: the duration o lhe treatment: drugs used in combination or coincidental with the specific compound employed: and like factors well known in the medical arts.
- the total daily dose of the compounds oflhe present invention administered to a human or lower mammal may range from about 0.01 to about 20 mg/kg/day. l or purposes of oral administration, more preferable doses may be in the range of from about 0.001 to about 3 mg/kg/day. If desired, the effective daily dose may be divided into multiple doses for purposes of administration: consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
- I opical administralion may involve doses ranging from 0.001 to 10 percent mg/kg/day. depending on the site of application. When administered locally to treat restenosis and vulnerable plaque, the dose may range from about I microgram '' mm stent length to about 100 microgram/mm stent length.
- compositions of the present invention comprise a compound and a pharmaceutically acceptable carrier or excipient. which may be administered orally, recta 11 ⁇ . parenteral ly . intracisternall . intrav aginally . intraperiionealry . topically (as by powders, ointments, drops or transdermal patch), hucally. or as an oral or nasal spray.
- pharmaceutical! acceptable earner means a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- parenteral. refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal. subcutaneous and intraarticular injection and infusion.
- compositions of the present invention for parenteral inieetion comprise pharmaceutical!) acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol. polyols (such as glycerol, propylene glycol, polyethylene gl eol. and the like), carboxv methylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
- Proper lluiditv ma) be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle si/e in the case of dispersions, and by the use of surfactants.
- I hese compositions mav also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms mav be ensured bv the inclusion of various antibacterial and antifungal agents, for example, paraben. chlorobutanol. phenol sorbic acid, and the like. It mav also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical fo m mav be brought about by the inclusion of agents w hich delay absorption such as aluminum monostearate and gelatin.
- Injectable depot forms arc made bv forming mieroencapsulc matrices of the drug in biodegradable polymers such as po laetide-polv gh colide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release may be controlled. I ' xamples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or niicroemulsions which arc compatible with body tissues.
- the injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which may be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutical I ⁇ acceptable excipient or carrier such as sodium citrate or dicaleium phosphate and/or a) tillers or extenders such as starches, lactose, sucrose, glucose, mannitol. and silicic acid, b) binders such as carboxy melliy lcellulose.
- the dosage form may also comprise b ffering agents.
- Solid composilions of a similar type may also be employed as fillers in soft, semi-solid and hard-filled gelatin capsules or liquid-lllled capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees. capsules, pills, and granules may be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition that they release the active ingredient(s) only, or preferentially , in a certain part of the intestinal tract, optionally, in a delayed manner, bxamples of embedding compositions which may be used include polymeric substances and waxes.
- the active compounds may also be in a micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- Liquid do>agc forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art. for example, water or other solvents, solubilizing agents and emulsi!lers such as ethyl alcohol, isopropvl alcohol, ethyl carbonate. ethyl acetate, benzyl alcohol, benzv I benzoale. propylene glycol. 1.3-butylene glycol, dimethyl I rmamide. oils (in particular, cottonseed, groundnut, corn. germ, olive, castor, and sesame oils), glycerol, tetrah drofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan. and mixtures thereof.
- inert diluents commonly used in the art. for example, water or other solvents, solubilizing
- the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, s eetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, s eetening, flavoring, and perfuming agents.
- Suspensions in addition to the active compounds, may contain suspending agents, for example, cthoxy lated isostcary I alcohols. polyoxy ethylene sorbitol and sorbitan esters, microcry stalline cellulose, aluminum metahydroxide. bentonite. agar--agar. and tragacanth. and mixtures thereof.
- suspending agents for example, cthoxy lated isostcary I alcohols. polyoxy ethylene sorbitol and sorbitan esters, microcry stalline cellulose, aluminum metahydroxide. bentonite. agar--agar. and tragacanth. and mixtures thereof.
- Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye.
- Compositions for topical administration may be prepared as a dry powder which may be pressurized or non-pressurized.
- the active ingredient in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter.
- Suitable inert carriers include sugars such as lactose. Desirably at least > percent by weight of the particles of the active ingredient have an effective particle size in the range of 0. 1 to 10 micrometers.
- Compositions for topical use on the skin also include ointments, creams, lotions, and gels.
- the composition may lie pressurized and contain a compressed gas. such as nitrogen or a liquefied gas propel lant.
- the liquelled propel lanl medium and indeed the total composition is preferably such that the active ingredient does not dissolve therein to any substantial extent.
- the pressurized composition may also contain a surface active agent.
- the surface active agent ma> be a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.
- a further form of topical administration is to the eye. as for the treatment of immune- mediated conditions of the eye such as autoimmune diseases, allergic or inflammatory conditions, and corneal transplants.
- I he compound of the present invention is delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye. as for example the anterior chamber, posterior chamber, vitreous bod). ac
- the pharmaceutical!) acceptable ophthalmic vehicle may. for example, be an ointment, vegetable oil or an encapsulating material.
- compositions for rectal or vaginal administration are preferably suppositories or retention enemas which may be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at bod) temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at bod) temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Liposomes are general! derived from phospholipids or other lipid substances, l iposomes are formed mono- or multi-lamellar hvdralcd liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologicall) acceptable and metaboli/able lipid capable of forming liposomes can be used.
- the present compositions in liposome form ma ⁇ contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients. and the like.
- the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and s nihetic. Methods to orm liposomes are known in the art. See. for example. Prescott. I d.. Methods in Cell Biology. Volume XIV. Academic Press. Ne York. N.Y. (1976). p.33 el seq.
- Compounds of the present invention may also be coadministered ith one or more immunosuppressant agents.
- the immunosuppressant agents within the scope of the present invention include IMURAN. RTM. a/athioprine sodium, brequinar sodium. SPANIDIN.RTM. gusperimus trih) drochloride (also known as dcoxyspergualiii). mizoribine (also known as bredinin).
- CI I I ⁇ PT.R I ' M. mofetil.
- NUORAI ..RTM Cylosporin A (also marketed as different formulation of Cyclosporin ⁇ under the trademark SANDIMMl : NI ..R ' l AT).
- PROCRAI .RTM. tacrolimus also known as l ' k ()6). sirolimus and RAPAMl NI ' .R I ' M., lellunomide (also known as IIW A-1 6).
- glucocorticoids such as prednisolone and its derivatives
- antibody therapies such as orthoclone (OK 1 ) and /cnapax.R I M.. and antith) mvocvie globulins, such as ihymoglobulins.
- the local deliver ⁇ of drug/drug combinations from a stent or other implantable device has the following advantages: namely, the prevention of vessel recoil and remodeling through the scaffolding action of the stent and the prevention of multiple components of neointimal hyperplasia or restenosis as well as a reduction in inflammation and thrombosis.
- This local administration of drugs, agents or compounds to stented coronary arteries may also have additional therapeutic benefit. l or example, higher tissue concentrations of the drugs, agents or compounds mav be achieved utilizing local delivery, rather than systemic administration. In addition, reduced systemic toxicity may be achieved utilizing local deliver ⁇ rather than systemic administration while maintaining higher tissue concentrations.
- a single procedure may suffice with better patient compliance.
- An additional benefit of combination drug, agent, and. or compound therapv mav be to reduce the dose of each of the therapeutic drugs, agents or compounds, thereby limiting their to icity . while still achieving a reduction in restenosis, inflammation and thrombosis.
- Local stent-based therapy is therefore a means of improving the therapeutic ratio (cHlcaey ⁇ toxicity) of anti-restenosis. anti-inllammalor ⁇ . antithrombotic drugs, agents or compounds.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/383,477 US20150051242A1 (en) | 2012-10-26 | 2012-11-30 | Rafamycin analogs and methods for making same |
CA2863243A CA2863243A1 (fr) | 2012-11-30 | 2012-11-30 | Analogue de la rapamycine et procedes de fabrication associes |
EP12889107.4A EP2809675A4 (fr) | 2012-11-30 | 2012-11-30 | Analogue de la rapamycine et procédés de fabrication associés |
JP2015544291A JP2016500112A (ja) | 2012-11-30 | 2012-11-30 | ラパマイシン類似体及びその製作方法 |
CN201280077424.7A CN104854112A (zh) | 2012-11-30 | 2012-11-30 | 雷帕霉素类似物及其制备方法 |
AU2012395673A AU2012395673A1 (en) | 2012-11-30 | 2012-11-30 | Rapamycin analogs and methods for making same |
SG11201404432QA SG11201404432QA (en) | 2012-11-30 | 2012-11-30 | Rafamycin analogs and methods for making same |
KR20147024024A KR20150003156A (ko) | 2012-11-30 | 2012-11-30 | 라파마이신 유사체 및 이의 제조 방법 |
PCT/CN2012/085631 WO2014082286A1 (fr) | 2012-11-30 | 2012-11-30 | Analogue de la rapamycine et procédés de fabrication associés |
ZA2014/05746A ZA201405746B (en) | 2012-11-30 | 2014-08-04 | Rafamycin analogs and methods for making same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/085631 WO2014082286A1 (fr) | 2012-11-30 | 2012-11-30 | Analogue de la rapamycine et procédés de fabrication associés |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014082286A1 true WO2014082286A1 (fr) | 2014-06-05 |
WO2014082286A9 WO2014082286A9 (fr) | 2014-11-13 |
Family
ID=50827071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/085631 WO2014082286A1 (fr) | 2012-10-26 | 2012-11-30 | Analogue de la rapamycine et procédés de fabrication associés |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2809675A4 (fr) |
JP (1) | JP2016500112A (fr) |
KR (1) | KR20150003156A (fr) |
CN (1) | CN104854112A (fr) |
AU (1) | AU2012395673A1 (fr) |
CA (1) | CA2863243A1 (fr) |
SG (1) | SG11201404432QA (fr) |
WO (1) | WO2014082286A1 (fr) |
ZA (1) | ZA201405746B (fr) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327097A (zh) * | 2014-10-11 | 2015-02-04 | 福建省微生物研究所 | 雷帕霉素的三氮唑衍生物和用途 |
CN104341434A (zh) * | 2014-10-16 | 2015-02-11 | 福建省微生物研究所 | 取代的雷帕霉素三氮唑衍生物和用途 |
CN104557975A (zh) * | 2014-12-23 | 2015-04-29 | 连云港恒运医药科技有限公司 | 依维莫司中间体及其降解杂质的制备方法 |
CN104876944A (zh) * | 2015-05-13 | 2015-09-02 | 上海适济生物科技有限公司 | 一种依维莫司的制备方法 |
CN105481704A (zh) * | 2016-01-12 | 2016-04-13 | 西安近代化学研究所 | 一种键合剂n-炔丙基二乙醇胺的合成与提纯方法 |
EP3061765A1 (fr) * | 2015-02-27 | 2016-08-31 | Warszawski Uniwersytet Medyczny | Dérivé de protoescigénine, son procédé de préparation, utilisation de ce composé et composition pharmaceutique comprenant ledit composé |
EP3109250A1 (fr) * | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Procede pour la synthese de derives de rapamycine |
WO2017038925A1 (fr) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | Composition pharmaceutique contenant de la rapamycine ou un dérivé de celle-ci |
CN109776569A (zh) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | 一种依维莫司的制备方法 |
CN112057425A (zh) * | 2020-09-30 | 2020-12-11 | 严鹏科 | 一种雷帕霉素制剂及其制备方法 |
US10980889B1 (en) | 2018-05-01 | 2021-04-20 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107759616B (zh) * | 2016-08-23 | 2020-11-17 | 上海微创医疗器械(集团)有限公司 | 一种化合物及其制备方法和用途 |
EP4119563A3 (fr) * | 2017-04-05 | 2023-04-05 | President And Fellows Of Harvard College | Composé macrocyclique et ses utilisations |
IL303660A (en) * | 2017-05-02 | 2023-08-01 | Revolution Medicines Inc | Rapamycin derivatives as MTOR tracers |
CN108484637A (zh) * | 2018-03-13 | 2018-09-04 | 福建省微生物研究所 | 靶向抗癌新药x-76成盐化合物及其用途、制备方法 |
CN109776571B (zh) * | 2019-01-31 | 2021-06-11 | 哈药慈航制药股份有限公司 | 一种雷帕霉素类似物及其制备方法和应用 |
CN115160343B (zh) * | 2022-06-09 | 2023-11-14 | 福建省微生物研究所 | 一种雷帕霉素衍生物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
WO1994009010A1 (fr) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | Derives o-alkyles de la rapamycine et leur utilisation, en particulier comme immunosuppresseurs |
WO1998009970A2 (fr) * | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Derives de rapamycine alkyles |
WO1998009972A1 (fr) * | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Derives de rapamycine presentant une stereochimie non naturelle |
WO1999015530A1 (fr) * | 1997-09-26 | 1999-04-01 | Abbott Laboratories | Analogues de rapamycine contenant du tetrazole a demi-vies raccourcies |
-
2012
- 2012-11-30 JP JP2015544291A patent/JP2016500112A/ja active Pending
- 2012-11-30 EP EP12889107.4A patent/EP2809675A4/fr not_active Withdrawn
- 2012-11-30 SG SG11201404432QA patent/SG11201404432QA/en unknown
- 2012-11-30 CN CN201280077424.7A patent/CN104854112A/zh active Pending
- 2012-11-30 KR KR20147024024A patent/KR20150003156A/ko not_active Application Discontinuation
- 2012-11-30 AU AU2012395673A patent/AU2012395673A1/en not_active Abandoned
- 2012-11-30 WO PCT/CN2012/085631 patent/WO2014082286A1/fr active Application Filing
- 2012-11-30 CA CA2863243A patent/CA2863243A1/fr not_active Abandoned
-
2014
- 2014-08-04 ZA ZA2014/05746A patent/ZA201405746B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009010A1 (fr) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | Derives o-alkyles de la rapamycine et leur utilisation, en particulier comme immunosuppresseurs |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
WO1998009970A2 (fr) * | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Derives de rapamycine alkyles |
WO1998009972A1 (fr) * | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Derives de rapamycine presentant une stereochimie non naturelle |
WO1999015530A1 (fr) * | 1997-09-26 | 1999-04-01 | Abbott Laboratories | Analogues de rapamycine contenant du tetrazole a demi-vies raccourcies |
Non-Patent Citations (1)
Title |
---|
See also references of EP2809675A4 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327097A (zh) * | 2014-10-11 | 2015-02-04 | 福建省微生物研究所 | 雷帕霉素的三氮唑衍生物和用途 |
CN104341434A (zh) * | 2014-10-16 | 2015-02-11 | 福建省微生物研究所 | 取代的雷帕霉素三氮唑衍生物和用途 |
CN104557975A (zh) * | 2014-12-23 | 2015-04-29 | 连云港恒运医药科技有限公司 | 依维莫司中间体及其降解杂质的制备方法 |
CN104557975B (zh) * | 2014-12-23 | 2017-06-20 | 连云港恒运医药有限公司 | 依维莫司中间体及其降解杂质的制备方法 |
EP3061765A1 (fr) * | 2015-02-27 | 2016-08-31 | Warszawski Uniwersytet Medyczny | Dérivé de protoescigénine, son procédé de préparation, utilisation de ce composé et composition pharmaceutique comprenant ledit composé |
US10370404B2 (en) | 2015-02-27 | 2019-08-06 | Warszawski Uniwersytet Medyczny | Protoescigenin derivative, process of its preparation, use of said compound and pharmaceutical composition comprising that compound |
WO2016135553A1 (fr) * | 2015-02-27 | 2016-09-01 | Warszawski Uniwersytet Medyczny | Dérivé de protoescigénine, son procédé de préparation, utilisation dudit composé et composition pharmaceutique le contenant |
CN104876944B (zh) * | 2015-05-13 | 2017-11-10 | 普济生物科技(台州)有限公司 | 一种依维莫司的制备方法 |
CN104876944A (zh) * | 2015-05-13 | 2015-09-02 | 上海适济生物科技有限公司 | 一种依维莫司的制备方法 |
WO2016207205A1 (fr) * | 2015-06-23 | 2016-12-29 | Synbias Pharma Ag | Procédé de synthèse de dérivés de rapamycine |
US10308665B2 (en) | 2015-06-23 | 2019-06-04 | Synbias Pharma Ag | Method for the synthesis of rapamycin derivatives |
EP3109250A1 (fr) * | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Procede pour la synthese de derives de rapamycine |
RU2718058C2 (ru) * | 2015-06-23 | 2020-03-30 | Синбиас Фарма АГ | Способ синтеза производных рапамицина |
WO2017038925A1 (fr) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | Composition pharmaceutique contenant de la rapamycine ou un dérivé de celle-ci |
CN105481704A (zh) * | 2016-01-12 | 2016-04-13 | 西安近代化学研究所 | 一种键合剂n-炔丙基二乙醇胺的合成与提纯方法 |
CN109776569A (zh) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | 一种依维莫司的制备方法 |
US10980889B1 (en) | 2018-05-01 | 2021-04-20 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11364300B2 (en) | 2018-05-01 | 2022-06-21 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
CN112057425A (zh) * | 2020-09-30 | 2020-12-11 | 严鹏科 | 一种雷帕霉素制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20150003156A (ko) | 2015-01-08 |
CN104854112A (zh) | 2015-08-19 |
CA2863243A1 (fr) | 2014-06-05 |
WO2014082286A9 (fr) | 2014-11-13 |
ZA201405746B (en) | 2015-11-25 |
SG11201404432QA (en) | 2014-10-30 |
AU2012395673A1 (en) | 2014-08-14 |
EP2809675A4 (fr) | 2015-08-12 |
AU2012395673A8 (en) | 2015-06-11 |
JP2016500112A (ja) | 2016-01-07 |
EP2809675A1 (fr) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014082286A1 (fr) | Analogue de la rapamycine et procédés de fabrication associés | |
ES2244087T3 (es) | Analogos de rapamicina que contienen tetrazol de vida media acortada. | |
EP1832592A2 (fr) | Isomères 15-C de rapamycine et de rapamycine 42-C EPI, leur procédé de fabrication et leur utilisation | |
US7678901B2 (en) | Rapamycin analogs containing an antioxidant moiety | |
US7622477B2 (en) | Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same | |
EP0729471A1 (fr) | Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs | |
US20070203171A1 (en) | Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same | |
WO1994021644A1 (fr) | Immunomodulateurs sous forme de macrolactames thio-heterocycliques | |
EP1826212A1 (fr) | Isomères et épimères 42 d'analogues d'ester de rapmycine, procédés de fabrication et d'utilisation correspondante | |
US20070225313A1 (en) | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same | |
US20150051242A1 (en) | Rafamycin analogs and methods for making same | |
US5561137A (en) | Thio-heterocyclic macrolactam immunomodulators | |
EP0689545A4 (fr) | IMMUNOREGULATEURS A l'AMIDE MACROCYCLIQUE ET A L'UREE | |
MXPA00002976A (en) | Tetrazole-containing rapamycin analogs with shortened half-lives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12889107 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012889107 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012889107 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 233835 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2015544291 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2863243 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2012395673 Country of ref document: AU Date of ref document: 20121130 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147024024 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14383477 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014023192 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112014023192 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140918 |